Merck to Divest CDMO Business to Lonza

Merck has signed a definitive agreement to divest its contract development and manufacturing organization (CDMO) business to Lonza for a mid-triple-digit million-euro amount. The transaction, expected to close in mid-2027, allows Merck to focus on innovation-driven businesses while positioning the CDMO business for growth under Lonza's dedicated platform. The deal includes Merck's CDMO operations across multiple US sites in California, Wisconsin, Missouri, and Indiana.